Indivior (NASDAQ:INDV) Sees Unusually-High Trading Volume

Indivior PLC (NASDAQ:INDV - Get Free Report) saw unusually-strong trading volume on Tuesday . Approximately 158,870 shares were traded during trading, a decline of 50% from the previous session's volume of 319,397 shares.The stock last traded at $9.51 and had previously closed at $10.02.

Wall Street Analyst Weigh In

A number of brokerages have commented on INDV. Piper Sandler initiated coverage on Indivior in a research report on Tuesday, July 23rd. They issued an "overweight" rating and a $22.00 price target for the company. Craig Hallum cut their price objective on Indivior from $37.00 to $24.00 and set a "buy" rating for the company in a research note on Wednesday, July 10th.

Indivior Stock Down 3.4 %

The company has a debt-to-equity ratio of 23.50, a quick ratio of 0.68 and a current ratio of 0.85. The company's 50-day moving average price is $12.34 and its 200 day moving average price is $16.61. The stock has a market capitalization of $1.33 billion, a P/E ratio of 963.00 and a beta of 0.69.

Indivior (NASDAQ:INDV - Get Free Report) last posted its quarterly earnings results on Thursday, July 25th. The company reported $0.44 EPS for the quarter, beating analysts' consensus estimates of $0.40 by $0.04. Indivior had a negative return on equity of 654.82% and a negative net margin of 12.29%. The business had revenue of $299.00 million for the quarter, compared to analysts' expectations of $285.90 million. As a group, equities analysts expect that Indivior PLC will post 1.74 earnings per share for the current year.

Institutional Investors Weigh In On Indivior

Institutional investors have recently added to or reduced their stakes in the stock. Norges Bank purchased a new stake in shares of Indivior in the fourth quarter worth about $36,011,000. UBS Group AG lifted its position in Indivior by 71.9% during the fourth quarter. UBS Group AG now owns 826,130 shares of the company's stock valued at $12,615,000 after purchasing an additional 345,556 shares during the last quarter. Renaissance Group LLC grew its stake in shares of Indivior by 6.1% in the 4th quarter. Renaissance Group LLC now owns 103,023 shares of the company's stock worth $1,573,000 after buying an additional 5,896 shares in the last quarter. Campbell & CO Investment Adviser LLC increased its holdings in shares of Indivior by 2.8% in the 4th quarter. Campbell & CO Investment Adviser LLC now owns 37,948 shares of the company's stock worth $573,000 after buying an additional 1,037 shares during the last quarter. Finally, Premier Fund Managers Ltd raised its position in shares of Indivior by 17.8% during the 4th quarter. Premier Fund Managers Ltd now owns 850,980 shares of the company's stock valued at $12,901,000 after buying an additional 128,611 shares in the last quarter. 60.33% of the stock is owned by hedge funds and other institutional investors.

Indivior Company Profile

Indivior PLC, together with its subsidiaries, engages in the development, manufacture, and sale of buprenorphine-based prescription drugs for the treatment of opioid dependence and co-occurring disorders in the United States, the United Kingdom, and internationally. The company develops medicines to treat substance use disorders, serious mental illnesses, and opioid overdose.